Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ad26.COV2.S Booster Study (Amplify)
NCT04999111Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2021
- Primary completion
- Oct 2021
- Modality
- Viral Vectors, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Ad26.COV2.S in coronavirus disease 2019 (COVID-19), sponsored by Janssen Pharmaceutical. Primary endpoints: Percentage of Participants With Serological Response Against SARS-CoV-2 Original Strain, Geometric Mean Titers (GMTs) of Neutralizing Antibodies Against SARS-CoV-2 Original Strain and 2 more. Started Aug 2021; status: completed.
02
Drugs
Ad26.COV2.S
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04999111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04999111.